MedPath

Phenobarbital

Generic Name
Phenobarbital
Brand Names
Donnatal, Luminal, Phenobarb, Phenohytro, Sezaby
Drug Type
Small Molecule
Chemical Formula
C12H12N2O3
CAS Number
50-06-6
Unique Ingredient Identifier
YQE403BP4D
Background

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

Indication

For the treatment of all types of seizures except absence seizures.

Associated Conditions
Alcohol Withdrawal Syndrome, Anxiety, Febrile Convulsions, Hyperbilirubinemia, Insomnia, Menopausal Symptoms, Partial-Onset Seizures, Seizures, Generalized, Withdrawal Symptoms
Associated Therapies
Sedation
Clinical Trials
Related News

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

Phase 4
Active, not recruiting
Conditions
Hypoxia-Ischemia, Brain
Brain Ischemia
Persistent Vegetative State
Brain Hypoxia
Heart Arrest
Stroke
Brain Injuries, Acute
Brain Injuries, Traumatic
Intracranial Hemorrhages
Coma
Interventions
Drug: Phosphenytoin
First Posted Date
2023-10-13
Last Posted Date
2025-02-12
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
54
Registration Number
NCT06081283
Locations
🇺🇸

UNC Health, Chapel Hill, North Carolina, United States

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Phase 2
Recruiting
Conditions
Seizure Newborn
Neonatal Seizure
Neonatal Encephalopathy
Hypoxic-Ischemic Encephalopathy
Interventions
First Posted Date
2022-11-09
Last Posted Date
2024-06-12
Lead Sponsor
University of California, San Diego
Target Recruit Count
133
Registration Number
NCT05610085
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇳🇿

Auckland City Hospital, Auckland, New Zealand

🇳🇿

Middlemore Hospital, Auckland, New Zealand

and more 1 locations

Lacosamide in Neonatal Status Epilepticus

Phase 3
Conditions
Epilepsy
Interventions
First Posted Date
2022-03-22
Last Posted Date
2022-03-22
Lead Sponsor
Sherief Abd-Elsalam
Target Recruit Count
60
Registration Number
NCT05291455
Locations
🇪🇬

Kafrelsheikh University, Tanta, Kafrelsheikh, Egypt

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

Phase 3
Terminated
Conditions
Epilepsy, Benign Neonatal
Interventions
First Posted Date
2020-03-25
Last Posted Date
2023-10-26
Lead Sponsor
NEMA Research, Inc.
Target Recruit Count
4
Registration Number
NCT04320940
Locations
🇺🇸

UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Marshall Health, Huntington, West Virginia, United States

🇺🇸

South Miami Hospital, Miami, Florida, United States

and more 5 locations

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

Phase 4
Conditions
Alcohol Withdrawal
Alcohol Withdrawal Delirium
Interventions
First Posted Date
2019-11-07
Last Posted Date
2020-10-08
Lead Sponsor
OSF Healthcare System
Target Recruit Count
142
Registration Number
NCT04156464
Locations
🇺🇸

OSF Saint Francis Medical Center, Peoria, Illinois, United States

Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine

Phase 4
Withdrawn
Conditions
Alcohol Withdrawal Syndrome
Interventions
Drug: Placebo A
Drug: Placebo B
First Posted Date
2018-12-28
Last Posted Date
2019-09-19
Lead Sponsor
Santa Barbara Cottage Hospital
Registration Number
NCT03788889

Selective Treatment According to Molecular Subtype of Prostate Cancer

Phase 2
Conditions
Prostate Cancer Metastatic
Castration-resistant Prostate Cancer
Interventions
Drug: Neuroendocrine type-1
Drug: Neuroendocrine type-2
Drug: Atypical type-1
Drug: Atypical type-2
First Posted Date
2018-10-04
Last Posted Date
2018-10-09
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
300
Registration Number
NCT03696186
Locations
🇨🇳

Tianjin Medical Unversity Second Hospital, Tianjin, China

Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome

Phase 2
Completed
Conditions
Neonatal Abstinence Syndrome
Interventions
First Posted Date
2018-09-13
Last Posted Date
2021-11-10
Lead Sponsor
University of Tennessee Medical Center
Target Recruit Count
25
Registration Number
NCT03670160
Locations
🇺🇸

University of Tennessee Medical Center, Knoxville, Tennessee, United States

Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting

Phase 3
Completed
Conditions
Pediatric Status Epilepticus
Interventions
First Posted Date
2018-08-28
Last Posted Date
2018-08-28
Lead Sponsor
University of Cape Town
Target Recruit Count
198
Registration Number
NCT03650270
Locations
🇿🇦

Red Cross War Memorial Children's Hospital, Cape Town, Western Cape, South Africa

Pharmacokinetics of Antiepileptics in Patients on CRRT

Completed
Conditions
Acute Kidney Injury
Renal Insufficiency
Renal Failure
Pharmacokinetics
Interventions
First Posted Date
2018-08-16
Last Posted Date
2021-10-05
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
18
Registration Number
NCT03632915
Locations
🇺🇸

University of Maryland Medical Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy